Latest Vaccines News

Page 3 of 4
CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.
Ada Torres
Ada Torres
19 Aug 2025
Imugene Limited reports strong clinical progress with its off-the-shelf CAR T therapy azer-cel achieving a 75% overall response rate in Phase 1b trials, alongside new patents and leadership appointments. The company also secured $22.5 million in fresh funding to advance pivotal trials.
Ada Torres
Ada Torres
31 July 2025
MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.
Ada Torres
Ada Torres
31 July 2025
MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.
Victor Sage
Victor Sage
31 July 2025
Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.
Ada Torres
Ada Torres
30 July 2025
Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.
Ada Torres
Ada Torres
4 July 2025
AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.
Victor Sage
Victor Sage
12 June 2025
MedAdvisor Solutions reported a challenging third quarter with steep revenue declines, driven by delayed program launches and US sales underperformance, but is executing a strategic overhaul and cost-cutting measures to position for a rebound and 15% revenue growth in FY26.
Ada Torres
Ada Torres
30 Apr 2025
MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.
Ada Torres
Ada Torres
30 Apr 2025
Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.
Ada Torres
Ada Torres
30 Apr 2025
CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.
Victor Sage
Victor Sage
11 Feb 2025
CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.
Ada Torres
Ada Torres
11 Feb 2025